IN8bio, Inc. Common Stock
$1.01
-$0.04 (-3.81%)
$1.01Day Range$1.09
Key Statistics
Market Cap
$10.35M
Shares Outstanding
9.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 30, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.06
Day High
$1.09
Day Low
$1.01
Volume
29.4K
VWAP
$1.05
Prev Close
$1.05
Transactions
--
Acc. Volume
--
About IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283618 employeesEMPIRE STATE BUILDING, NEW YORK, NY, 10118(646) 600-6438IPO Jul 30, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001740279
- Composite FIGI
- BBG00XX9K1M2
- Share Class FIGI
- BBG00XX9K2G7
- Ticker Root
- INAB
- SIC Code
- 2836
About IN8bio, Inc. Common Stock (INAB) Stock
IN8bio, Inc. Common Stock (INAB) closed the 2026-09-16 session at $1.01, down 3.81% versus the previous close (-0.04). The stock opened at $1.06 and traded between $1.01 and $1.09 during that session. Session trading volume was 29K shares. The volume-weighted average price (VWAP) is $1.05.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
IN8bio, Inc. Common Stock has a market capitalization of $10.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. INAB is listed on the XNAS exchange. The company employs approximately 18 people. IN8bio, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2021-07-30.
On this page you can find market INAB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.